Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Journal of Molecular Biology|July 27, 2011
Synthetic antibodies designed on natural sequence landscapesWenwu Zhai, Jacob Glanville, Markus Fuhrmann, et al.
Bioinformatics (Oxford, England)|October 25, 2012
A method for integrative structure determination of protein-protein complexesDina Schneidman-Duhovny, Andrea Rossi, Agustin Avila-Sakar, et al.
Mabs|December 21, 2019
Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic modelsFeng Wang, Jordan C Tsai, Jonathan H Davis, et al.
Scientific Reports|February 23, 2019
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugatesMaria José Costa, Jyothirmayee Kudaravalli, Jing-Tyan Ma, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 25, 2011
Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primatesHong Liang, Javier Chaparro-Riggers, Pavel Strop, et al.
Molecular Cancer Therapeutics|March 6, 2016
Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker DesignMagdalena Dorywalska, Russell Dushin, Ludivine Moine, et al.
The Journal of Biological Chemistry|February 2, 2012
Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9Javier Chaparro-Riggers, Hong Liang, Rachel M DeVay, et al.
Journal of Molecular Biology|October 7, 2014
Precise and efficient antibody epitope determination through library design, yeast display and next-generation sequencingThomas Van Blarcom, Andrea Rossi, Davide Foletti, et al.
Molecular Cancer Therapeutics|August 28, 2020
Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 AntibodyAmir A Al-Khami, Sawsan Youssef, Yasmina Abdiche, et al.
Pageof 7